Company Overview of XDx, Inc.
XDx, Inc. operates as a molecular diagnostics company that discovers, develops, and commercializes noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company focuses on immune-mediated conditions that require life-long monitoring and testing to avoid or to respond to serious complications. It offers AlloMap HTx molecular expression test to monitor heart transplant recipients for acute cellular rejection; AlloMap LTx molecular expression test, a gene expression-based test to monitor cellular rejection in lung transplant recipients; and AlloMap molecular expression testing for non-invasive blood test that aids physicians in determini...
3260 Bayshore Boulevard
Brisbane, CA 94005
Founded in 1998
Key Executives for XDx, Inc.
Chief Executive Officer and President
Vice President of Finance and Commercial Operations
Chief Medical Officer and Executive Vice President
Vice President of Technical Operations and Senior Director of Xdx Reference Laboratory
Compensation as of Fiscal Year 2013.
XDx, Inc. Key Developments
Diaxonhit and XDx, Inc. Enter into Definitive Exclusive License and Distribution Agreement
Jun 27 13
Diaxonhit and XDx, Inc. announced that they have entered into a definitive exclusive license and distribution agreement to market and perform AlloMap Molecular Expression Testing (AlloMap(R)) in Europe. Diaxonhit shareholders approved the issuance of warrants and stock to XDx during the annual meeting held on June 20, 2013, thereby clearing the final step for the license agreement to become effective. Diaxonhit will promote AlloMap in Europe through its wholly owned subsidiary, InGen, the leader in France for marketing tests related to transplantation and histocompatibility testing.
CML HealthCare Inc. and XDx, Inc. Announce Exclusive Licensing Agreement to Market and Distribute Allomap(R) Heart Transplant Test
Jun 20 13
CML HealthCare Inc. and XDx, Inc. entered into an exclusive licensing agreement that provides CML HealthCare with exclusive rights, initially in Ontario, to AlloMap, XDx's flagship diagnostic blood test used by physicians to identify heart transplant recipients who have a low probability of acute cellular rejection. The agreement also provides the Company with the option to extend the distribution and marketing rights to AlloMap across Canada. AlloMap has been marketed by XDx in the United States since 2005 and is CLIA certified, FDA cleared and CE marked. It will be available in AlloMap testing will be performed by XDx in its CLIA laboratory in Brisbane, California. There are approximately 165 heart transplants performed annually in Canada. Currently, as part of the overall management of heart transplant patients, multiple invasive heart biopsies are performed, especially during the early years post-transplant. In comparison, the AlloMap Test is a simple, non-invasive blood test.
Diaxonhit and XDx Sign Memorandum of Agreement to Market AlloMap in Europe
Jun 20 13
Diaxonhit and XDx, Inc. have entered into a memorandum of agreement for the exclusive license to market and perform AlloMap Molecular Expression Testing in Europe. Entering into this exclusive license agreement demonstrates the ability of new group to successfully carry out its strategy of growth and development. The medical benefits of AlloMap and its success in the US give confidence in a rapid adoption in Europe. With European CARGO II validation study completed in 2012, Diaxonhit can build on the tremendous efforts XDx has invested in AlloMap. The strengths of Diaxonhit in the field of transplantation convinced to grant Diaxonhit an exclusive license. In return for this exclusive European license, XDx will receive an upfront payment upon signature of the definitive agreement, future royalties based on European sales, and milestone payments based on sales performance. These payments will be made in cash and Diaxonhit stock.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|